About Us

PrECOG aligns with and supports the goals of the ECOG-ACRIN Cancer Research Group executive leadership, and builds upon them through innovative studies developed in collaboration with industry, research networks, and individuals.

About Us

Overview

The governing structure of PrECOG is comprised of a Board of Managers, including a Chair/CEO, Director of Operations, and five physician members drawn from the ECOG-ACRIN Cancer Research Group leadership and academic teams. All are prominent thought leaders within ECOG-ACRIN Cancer Research Group, and in their institutions of primary affiliation.

PrECOG’s clinical trial sites represent an established network of institutions, many with master service agreements that facilitate study start-up activities, thus providing the leverage of strong existing site relationships that foster high-quality performance.

PrECOG offices are conveniently located in Center City, Philadelphia, a city rich in history, culture, and dining options. Our offices are easily accessible by rail, air, or car.

 

Our Leadership

Our Operations team includes experienced project management, regulatory, statistical, monitoring, and support personnel.

Peter O’Dwyer, MD
Peter O’Dwyer, MD
CEO and Chair
Peter O’Dwyer, MD

Peter O’Dwyer, MD

CEO and Chair

Dr. O’Dwyer is the PrECOG, LLC Board of Managers Chair and CEO. He is a medical oncologist at the University of Pennsylvania, where he holds an appointment as Professor of Medicine. His research focus is in the area of novel therapy development, primarily in pancreatic and colorectal cancers. Since 2017, he has served as Group Co-Chair for ECOG-ACRIN Cancer Research Group, where he also leads the GI Cancer Committee.

Donna Marinucci
Donna Marinucci
Executive Director
Donna Marinucci

Donna Marinucci

Executive Director

Donna Marinucci serves as Executive Director on the PrECOG Board of Managers, and has oversight for study start and management. She is the Executive Director of ECOG-ACRIN Cancer Research Group. She is also Vice President of the Coalition of Cancer Cooperative Groups and its subsidiary, Alpha Oncology. Her career in oncology research in the academic management space has spanned over 25 years.

Board of Managers

Al Benson, MD
Al Benson, MD
Al Benson, MD

Al Benson, MD

Dr. Benson is a Professor of Medicine in Hematology/Oncology at Northwestern University Feinberg School of Medicine and Associate Director for Cooperative Groups at Robert H. Lurie Comprehensive Cancer Center. At ECOG-ACRIN, he is a member of the Principal Investigator Committee, and Co-Chair of the NCORP Advisory Committee and the Cancer Care Delivery Research Committee. He also chairs both the Therapeutic and PrECOG Data Safety Monitoring Committees. His primary research focus is gastrointestinal cancers.

Bruce Giantonio, MD
Bruce Giantonio, MD
Bruce Giantonio, MD

Bruce Giantonio, MD

Dr. Giantonio is a medical oncologist at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Giantonio also serves as Executive Officer for ECOG-ACRIN Cancer Research Group.

Joseph Sparano, MD
Joseph Sparano, MD
Joseph Sparano, MD

Joseph Sparano, MD

Dr. Sparano is Professor of Medicine and Women’s Health at the Albert Einstein College of Medicine, Associate Chairman in the Department of Oncology at Montefiore Medical Center, and Associate Director for Clinical Research at the Albert Einstein Cancer Center. He is a medical oncologist whose research has focused on developmental therapeutic approaches for breast cancer and HIV-associated cancers, and clinical application biomarkers in breast cancer.

Patrick Flynn, MD
Patrick Flynn, MD
Patrick Flynn, MD

Patrick Flynn, MD

Dr. Flynn was past Principal Investigator of the Metro Minnesota Community Cooperative Oncology Research Consortium (previously Metro-Minnesota CCOP). He is a Board Member of the ECOG-ACRIN Research Foundation and past Co-Chair of the ECOG-ACRIN Cancer Research Group Community Cancer Committee.

Suresh Ramalingam, MD
Suresh Ramalingam, MD
Suresh Ramalingam, MD

Suresh Ramalingam, MD

Dr. Ramalingam is Professor of Hematology and Medical Oncology and Assistant Dean for Cancer Research at Emory University School of Medicine. He is also the Roberto C. Goizueta Chair for Cancer Research and the Deputy Director of the Winship Cancer Institute of Emory University. Dr. Ramalingam’s specialty is thoracic oncology.

What PrECOG Offers

Research Development

Ideas for PrECOG clinical trials arise from the ECOG-ACRIN Cancer Research Group Scientific Committees and are proposed by the committee, individual committee members, or via a collaborative relationship with industry partners or other research companies. PrECOG studies align with, expand, and support the goals of the ECOG-ACRIN Cancer Research Group executive leadership.

To inquire further about research collaborations please contact PrECOG.

Research Support

Identifying tumor biomarkers and genetic/genomic signatures has led to a revolution in cancer care, allowing oncologists to target specific treatments to those patients most likely to respond. Thus, exploring additional markers for patient selection or tumor response to investigational therapy is of primary importance in clinical trial design and evaluation. PrECOG utilizes central laboratories for consistency in tissue banking and correlative biomarker and patient imaging evaluations.

To inquire further about research collaborations, please contact PrECOG.

PrECOG Study Sites

PrECOG sites currently include representation from U.S. and international research networks, community and NCI-designated cancer centers, academic institutions, and individual research practices with extensive oncology research experience. These sites are members of ECOG-ACRIN Cancer Research Group and the NCTN. Many have master agreements with PrECOG which can facilitate study activation.

Go to Trials

Study Operational Oversight

The PrECOG Operations Team provides oversight and monitoring of all studies to ensure patient safety, data integrity, and data validity. Clinical trial oversight is determined by the nature of any collaboration, but is commensurate with the anticipated safety risks, size, and complexity of the clinical trial. Study management standards include central registration/randomization and electronic data capture (EDC). Study systems and supporting materials are developed to meet all known ICH and GCP requirements.

If determined that the study requires independent data safety monitoring oversight, the PrECOG Global Data and Safety Monitoring Board (DSMB) will monitor subject safety, scientific integrity of the clinical trial, and data validity. The DSMB also monitors accrual against timelines, the quality of data collection and management, and other outcomes.